Introduction
============

Colorectal cancer is one of the most common malignancies and among the leading causes of cancer-related deaths worldwide. [@B1] Researchers have recently focused on analyzing the diversity of molecular profiles within the large intestine; [@B2] there is also renewed interest in clinicopathologic features as prognostic and predictive indicators, such as side (i.e., right vs. left) of the primary tumor [@B3] and histologic type (i.e., mucinous vs. non-mucinous). [@B4]

Previous studies have shown that compared to patients with left-sided colon cancer (LSCC), those with right-sided colon cancer (RSCC) tend to be older and of the female gender, and have poorly differentiated and advanced stage tumors. [@B5]-[@B7] Additionally, RSCC exhibits a different molecular profile from LSCC. [@B8]-[@B10] However, data comparing prognosis between RSCC and LSCC are conflicting, particularly when patients are stratified by tumor stage. [@B3], [@B6], [@B7], [@B11], [@B12]

Mucinous adenocarcinoma (MAC) is a tumor comprising more than 50% extracellular mucin. [@B13] MAC is more often correlated with right sidedness, advanced stage at presentation, and peritoneal dissemination, and has different molecular biological patterns than non-mucinous adenocarcinoma (NMAC). [@B4], [@B14]-[@B16] However, the prognostic value of the mucinous histology remains controversial. Several studies reported that MAC was associated with poor prognosis, [@B16]-[@B18] while others did not confirm this conclusion. [@B4], [@B19]-[@B21]

To our knowledge, data are scarce regarding the prognostic impact of sidedness and histology stratified by each other. We suspect that non-mucinous RSCC, non-mucinous LSCC, mucinous RSCC, and mucinous LSCC might represent different disease entities. In the present population-based study of patients with stage II-IV colon cancer, we aim to investigate whether the prognostic impacts of tumor side and histology on patient survival differ according to each other.

Materials and Methods
=====================

Study cohort
------------

Using the National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) database (18 registries), we identified 254040 patients with colon cancer diagnosed between January 2004 and December 2012. As presented in **Figure [1](#F1){ref-type="fig"}**, 81342 patients met the inclusion criteria for this study. Because SEER is public-use data, no institutional review was sought and informed consent was waived.

Overall survival (OS) was the primary outcome of interest. The examined covariates included race, age, sex, marital status, year of diagnosis, SEER region, tumor grade, tumor location, tumor histologic type, T and N category (6^th^ edition), and the total number of lymph nodes evaluated.

Patients with cancer of the cecum, ascending colon, and transverse colon were defined as having RSCC, and patients with cancer of the descending or sigmoid colon were considered as having LSCC. NMAC was defined on the basis of the third edition of the International Classification of Diseases for Oncology histology codes 8140, 8144, 8210, 8211, 8221, 8261, 8262, and 8263 and MAC, on the basis of the codes 8480 and 8481. Patients were further divided into four subgroups on the basis of sidedness and histology (S-H): non-mucinous RSCC, non-mucinous LSCC, mucinous RSCC, and mucinous LSCC.

This study is based on SEER database which is public-use data, thus no institutional review was sought and informed consent was waived.

Statistical analysis
--------------------

The χ^2^ test was used to compare baseline clinicopathologic features between the S-H groups. To allow for more accurate measurement of the prognostic impact of sidedness and histology, we used an inverse probability propensity score weighting approach for multiple groups (≥ 2) [@B22] with stratification for tumor stage to generate a weighted cohort in which the clinicopathologic features (i.e., age, sex, race, marital status, year of diagnosis, SEER region, tumor grade, T and N stage, and total evaluated lymph node count) were balanced between each pair of S-H groups. Propensity score methods are useful to reduce or minimize the effects of confounding when estimating the effects of treatments, exposures, or interventions in observational or non-randomized interventional studies. [@B23] It has been shown that that both the inverse propensity score weighting and propensity score matching allow for the estimation of the causal effect with minimal bias. [@B24] As compared with the propensity score matching approach, inverse propensity score weighting can be more flexibly applied to comparison between multiple groups and hence was used in the current study. [@B22], [@B25]

After inverse propensity score weighting, OS was compared between the RSCC and LSCC groups and between the MAC and NMAC groups, as well as among the S-H groups. Survival curves for patients in different groups were generated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards models with inverse propensity score weighting and robust sandwich variance estimators [@B26] were used to assess the associations of sidedness, histology, and S-H group with hazard ratios (HRs) for death. Interaction tests were performed to determine whether the impacts of sidedness and histology on OS were significantly influenced by each other using Cox proportional hazards models.

Statistical significance was set as *P* \< 0.050 in a two-tailed test. Statistical analyses were performed using SAS v. 9.3 (SAS Institute, Cary, NC, USA), IBM SPSS Statistics for Windows v. 19.0 (IBM Corp., Armonk, NY, USA), and R v. 3.4.1 (<http://www.r-project.org>).

Results
=======

Patient characteristics
-----------------------

**Table [1](#T1){ref-type="table"}** summarizes the patient characteristics of the study cohort (81342 cases). Overall, 49,398 (60.7%) patients had RSCC and 31,944 (39.3%) patients had LSCC, 9265 (11.4%) patients with MAC while 72077 (88.6%) patients with NMAC. The non-mucinous RSCC, non-mucinous LSCC, mucinous RSCC, and mucinous LSCC subgroups included 42395 (52.1%), 29682 (36.5%), 7003 (8.6%), and 2262 (2.8%) patients, respectively. The mean follow-up duration was 35.7 ± 29.3 months.

As shown in **Table [2](#T2){ref-type="table"}**, MAC was more often present on the right side of the colon (14.2% vs. 7.1%, *P* \< 0.001). Because of the large sample size, statistically significant imbalances were detected in all patient characteristics between the RSCC and LSCC groups (except year of diagnosis) and between the MAC and NMAC groups. However, absolute differences in the proportions were numerically small. Of note, compared to patients with LSCC, those with RSCC were markedly more likely to be female (55.3% vs. 47.8%), non-Hispanic white (71.2% vs. 65.7%), and older than 80 years of age (26.3% vs. 15.3%), and they had poorly or non-differentiated (27.4% vs. 17.1%) tumors, stage II tumors (43.3% vs. 37.3%), and ≥ 12 evaluated nodes (80.0% vs. 69.5%). More patients with MAC had T4 disease (25.2% vs. 18.4%) compared to patients with NMAC.

After inverse propensity score weighting, patient characteristics were well balanced between each pair of the four S-H groups in all three stage subgroups (**Supplementary Tables A-C**).

Prognostic impact of sidedness in stage II-IV subgroups
-------------------------------------------------------

After inverse propensity score weighting, the median OS was significantly better in LSCC than in RSCC in the stage IV subgroup (20.5 vs. 16.5 months; HR for RSCC, 1.15 \[95% CI, 1.11-1.19\]; P \< 0.001; **Figure [2](#F2){ref-type="fig"}A**). The weighted 3-year OS rates for RSCC and LSCC were numerically similar in the stage III (68.6% and 69.9%, respectively; **Figure [2](#F2){ref-type="fig"}B**) and stage II subgroups (81.3% and 80.5%, respectively; **Figure [2](#F2){ref-type="fig"}C**), although the differences were statistically significant due to the large sample size (stage III subgroup: HR for RSCC, 1.06 \[95% CI, 1.01-1.09\]; P = 0.006; stage II subgroup: HR for RSCC, 0.93; 95% CI, 089-0.97; P = 0.006).

Prognostic value of mucinous histology by stage
-----------------------------------------------

The weighted OS was significantly worse for MAC than NMAC in the stage IV (median OS, 16.9 vs. 19.5 months; HR for MAC, 1.15 \[95% CI, 1.09-1.22\]; *P* \< 0.001; **Figure [3](#F3){ref-type="fig"}A**) and stage III subgroups (3-year OS, 67.0% vs. 71.5%; HR for MAC, 1.13 \[95% CI, 1.07-1.19\]; *P* \< 0.001; **Figure [3](#F3){ref-type="fig"}B**). In the stage II subgroup, the weighted 3-year OS rates were similar for MAC and NMAC (81.0% and 80.8%, respectively; HR for MAC, 1.01 \[95% CI, 0.88-1.16\]; *P* = 0.853; **Figure [3](#F3){ref-type="fig"}C**).

In the stage III subgroup with inverse propensity score weighting, the prognostic interaction between sidedness and histology was also statistically significant (*P~interaction~* \< 0.001; **Figure [4](#F4){ref-type="fig"}B** and **Table [3](#T3){ref-type="table"}**). The prognosis for non-mucinous RSCC was worse than for non-mucinous LSCC (3-year OS: 69.0% vs. 73.9%; HR, 1.14 \[95% CI, 1.10-1.19\]; P \< 0.001), whereas the prognosis for mucinous RSCC was similar to that for mucinous LSCC (3-year OS: 68.2% vs. 65.6%; HR, 0.96 \[95% CI, 0.85-1.09\]; P = 0.531). The prognosis for MAC on the left-hand side was markedly worse than NMAC on this side (3-year OS: 65.6% vs. 73.9%; HR, 1.23 \[95% CI, 1.11-1.38\]; P \< 0.001), whereas the survival rates for MAC and NMAC on the right-hand side were similar (3-year OS: 68.2% vs. 69.0%; HR, 1.04 \[95% CI, 0.97-1.11\]; P = 0.300).

In the stage II subgroup, the weighted 3-year OS rates were similar between the non-mucinous RSCC, non-mucinous LSCC, mucinous RSCC, and mucinous LSCC groups (81.0%, 80.6%, 81.6%, and 80.5%, respectively; *P* = 0.159; **Figure [4](#F4){ref-type="fig"}C** and**Table [3](#T3){ref-type="table"}**). Additionally, the interaction between tumor side and histology was insignificant *(P~interaction~* = 0.466).

Prognostic interaction between tumor side and histology
-------------------------------------------------------

In the stage IV subgroup weighted by inverse propensity score, the impact of sidedness on survival significantly differed according to tumor histology, and vice versa (test for interaction between sidedness and histology, *P~interaction~* \< 0.001; **Figure [4](#F4){ref-type="fig"}A** and**Table [3](#T3){ref-type="table"}**). Patients with non-mucinous RSCC showed an 8-month decrease in median OS compared to those with non-mucinous LSCC (16.5 vs. 24.5 months; HR, 1.26 \[95% CI, 1.21-1.31\]; P \< 0.001), whereas patient survival was similar for mucinous RSCC and mucinous LSCC (median OS: 16.5 months for both; HR for mucinous RSCC, 1.03 \[95% CI, 0.92-1.16\]; P = 0.570). Additionally, mucinous LSCC demonstrated an 8-month decrease in median OS compared with non-mucinous LSCC (16.5 vs. 24.5 months; HR, 1.27 \[95% CI, 1.14-1.41\]; P \< 0.001), whereas patient survival was similar for mucinous RSCC and non-mucinous RSCC (median OS: 16.5 months for both; HR for mucinous RSCC, 1.05 \[95% CI, 0.97-1.12\]; P = 0.207).

Sensitivity analysis
--------------------

For sensitivity analysis, we repeated the primary analyses after excluding patients with transverse colon cancer (10536 cases) or re-classifying these patients into the LSCC group. Additionally, we repeated the analyses after excluding patients in the tails of the distribution of propensity scores. [@B27] Under these circumstances, the conclusions were consistent with those of the primary analyses (data not shown).

Discussion
==========

To the best of our knowledge, this is the first study that demonstrates that the prognostic impacts of tumor side and mucinous histology are affected by each other in stage III-IV colon cancer; that is, the prognosis for non-mucinous LSCC was significantly better than that for non-mucinous RSCC and that for mucinous LSCC, whereas the survival was similar between left-sided and right-sided MAC, and between mucinous and non-mucinous RSCC. In contrast, the survival was comparable among the four S-H subgroups for stage II colon cancer.

A number of previous studies have investigated the impact of sidedness and histology on survival outcomes for patients with colon cancer, reaching inconsistent conclusions. [@B3], [@B4], [@B6], [@B7], [@B11], [@B12], [@B19]-[@B21] None of these studies has taken into account sidedness, histology, and tumor stage simultaneously; to our knowledge, this is the first study to perform elaborate survival analyses with stratification for sidedness, histology, and tumor stage. The non-straightforward prognostic impact of sidedness and histology across different tumor stages, as well as the prognostic interaction between sidedness and histology for stage III/IV tumors, might partially explain the conflicting data in the previous studies.

Since clinicopathologic factors are optimally balanced by inverse propensity score weighting, tumor biology most probably drives the complex association of sidedness and histology with survival. Not only unfavorable molecular features (e.g., BRAF mutation, KRAS mutation, and CpG island methylation) but also favorable ones (e.g., deficient DNA mismatch repair \[dMMR\], chromosome stability and diploid) are more common in RSCC and MAC. [@B8], [@B9], [@B16], [@B28]-[@B32] As shown previously, the overall percentage of dMMR was up to 22% in stage II colon cancer, [@B33] which could partially balance out the negative prognostic impact of right sidedness and mucinous histology in the stage II subgroup. Moreover, the efficacy of chemotherapy and biologic agents may differ according to tumor side and histology, particularly in stage IV colon cancer. In the *post hoc* analysis of the FIRE1 trial, LSCC showed greater benefit from first-line cytotoxic chemotherapy than RSCC. [@B34] Additionally, reports of subgroup analysis from the FIRE3 and CALGB/SWOG 80405 trials suggest that patients with RSCC benefit less from anti-EGFR therapy than those with LSCC. [@B3], [@B35] Moreover, it was reported that MAC showed a poorer response to cytotoxic chemotherapeutic regimens than NMAC. [@B15], [@B16], [@B36] In the present study, the presence of either right sidedness or mucinous histology was correlated with an 8-month decrease in median OS and an over 25% increase in risk of death as compared with non-mucinous left-sided tumors in the stage IV subgroup, and the prognoses were similarly poor for stage IV non-mucinous RSCC, mucinous RSCC, and mucinous LSCC (16.5 months for all). Taken together, these findings suggest that both sidedness and histology should be considered during clinical decision-making processes and adopted as risk-stratification factors for advanced colon cancer. Moreover, recent studies suggest that despite dismal prognosis, the Commonsense Molecular Subtype 1 (predominantly right-sided tumors) and MAC are more likely to have a higher mutation count and stronger immune infiltration and activation.[@B2], [@B37] Therefore, further researches are warranted to investigate whether right-sidedness and/or mucinous histology can be used as additional markers to dMMR or high microsatellite instability for selecting candidates for PD-1 blockade. [@B38], [@B39]

The therapeutic value of adjuvant chemotherapy in stage II colon cancer remains controversial, highlighting the need for effective risk-stratifying factors. Previous studies showed that the efficacy of adjuvant chemotherapy did not differ between stage II RSCC and LSCC or between stage II MAC and NMAC. [@B17], [@B19] Because of lack of evidence, current guidelines do not include right-sidedness and mucinous histology in the risk factor list for decision-making regarding adjuvant chemotherapy. [@B40] In the current study, the survival was similar in the four S-H groups for stage II colon cancer, which supports the current recommendation that consider neither of these factors when evaluating the administration of adjuvant treatment for stage II colon cancer.

The present study has some limitations. First, only limited data on patient-level characteristics have been provided by the SEER database, whereas data on patient comorbidities and performance status, tumor molecular features, and chemotherapy and chemotherapeutic regimens are unavailable. Because we assessed OS as the endpoint, medical comorbidities or other competing causes of death might influence our results. Still, OS is the most valuable endpoint for cancer patients and has no difference in definition between hospitals. Moreover, although the definition of the mucinous histology has been standardized, there might be variations in the diagnosis depending on the interpretation of the individual pathologist, which might result in misclassification. Despite these limitations, given the large sample size and the population-based nature of the SEER database, we are able to perform adequately powered survival analyses stratified by tumor side, histology, and stage, which is hard to achieve with single-institution studies.

Conclusion
==========

In conclusion, the prognostic values of right sidedness and mucinous histology were mutually influenced for stage III and IV colon cancer. In contrast, the impacts of sidedness and histology on survival were minimal and independent of each other for stage II colon cancer. Thus, we recommend including both sidedness and histology as risk-stratification factors for patients with stage III/IV colon cancer but neither for those with stage II colon cancer.

We feel grateful that this work was supported by the Natural Science Foundation of Guangdong Province \[grant number 2014A030312015\]; Science and Technology Program of Guangdong \[grant number 2015B020232008\]; Science and Technology Program of Guangzhou \[grant number 15570006, 201508020250, 201604020003\]. We also thank the staff members of the National Cancer Institute and their colleagues across the United States and at Information Management Services, Inc., who have been involved with the Surveillance, Epidemiology, and End Results (SEER) Program.
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###### 

Clinicopathologic characteristics of the study cohort of patients with stage II-IV colon cancer (N = 81342)

  Variable                         Number (%)
  -------------------------------- ---------------
  **Tumor side**                   
  Right                            49398 (60.7%)
  Left                             31944 (39.3%)
  **Mucinous histology**           
  Yes                              9265 (11.4%)
  No                               72077 (88.6%)
  **S-H group**                    
  Non-mucinous RSCC                42395 (52.1%)
  Non-mucinous LSCC                29682 (36.5%)
  Mucinous RSCC                    7003 (8.6%)
  Mucinous LSCC                    2262 (2.8%)
  **Age, years**                   
  \< 50                            9153 (11.3%)
  50-59                            15133 (18.6%)
  60-69                            19170 (23.6%)
  70-79                            20017 (24.6%)
  ≥ 80                             17869 (22.0%)
  **Sex**                          
  Male                             38748 (47.6%)
  Female                           42594 (52.4%)
  **Race**                         
  Non-Hispanic white               56190 (69.1%)
  Non-Hispanic black               10079 (12.4%)
  Hispanic                         8047 (9.9%)
  Other                            7026 (8.6%)
  **Marital status**               
  Married                          45364 (55.8%)
  Single/other                     20034 (24.6%)
  Widowed                          15944 (19.6%)
  **Year of diagnosis**            
  2004-2006                        27968 (34.4%)
  2007-2009                        27785 (34.2%)
  2010-2012                        25589 (31.5%)
  **SEER region**                  
  Midwest                          13160 (16.2%)
  Northeast                        12780 (15.7%)
  South                            15823 (19.5%)
  West                             39579 (48.7%)
  **Tumor grade**                  
  G1/G2                            62334 (76.6%)
  G3/G4                            19008 (23.4%)
  **T stage**                      
  T1                               1521 (1.9%)
  T2                               3226 (4.0%)
  T3                               60978 (75.0%)
  T4                               15617 (19.2%)
  **N stage**                      
  N0                               36044 (44.3%)
  N1                               26624 (32.7%)
  N2                               18674 (23.0%)
  **AJCC stage**                   
  II                               33414 (41.1)
  III                              32480 (39.9)
  IV                               15448 (19.0)
  **Total evaluated node count**   
  \< 12                            19635 (24.1%)
  ≥ 12                             61707 (75.9%)

RSCC, right-sided colon cancer; LSCC, left-sided colon cancer; SEER, Surveillance, Epidemiology, and End Results; AJCC, American Joint Committee on Cancer

###### 

Patient characteristics of the study cohort stratified by tumor side and histology

  Variable                         RSCC (%)   LSCC (%)   *P* value   NMAC (%)   MAC (%)   *P* value
  -------------------------------- ---------- ---------- ----------- ---------- --------- -----------
  **Mucinous histology**                      \< 0.001                          \-        
  Yes                              14.2       7.1                    \-         \-        
  No                               85.8       92.9                   \-         \-        
  **Age, years**                                         \< 0.001                         \< 0.001
  \< 50                            8.6        15.3                   11.6       11.2      
  50-59                            15.6       23.3                   16.3       18.9      
  60-69                            22.9       24.7                   22.3       23.7      
  70-79                            26.7       21.4                   25.4       24.5      
  ≥ 80                             26.3       15.3                   24.3       21.7      
  **Sex**                                                \< 0.001                         0.012
  Male                             44.7       52.2                   46.4       47.8      
  Female                           55.3       47.8                   53.6       52.2      
  **Race**                                               \< 0.001                         \< 0.001
  Non-Hispanic white               71.2       65.7                   71.9       68.7      
  Non-Hispanic black               12.6       12.0                   11.6       12.5      
  Hispanic                         9.3        10.9                   10.1       9.9       
  Other                            6.9        11.4                   6.3        8.9       
  **Marital status**                                     \< 0.001                         \< 0.001
  Married                          54.2       58.2                   54.3       56.0      
  Widowed                          22.5       15.1                   21.7       19.3      
  Single/other                     23.3       26.7                   24.0       24.7      
  **Year of diagnosis**                                  0.154                            \< 0.001
  2004-2006                        34.2       34.7                   39.4       33.7      
  2007-2009                        34.1       34.2                   31.9       34.4      
  2010-2012                        31.7       31.1                   28.7       31.8      
  **SEER region**                                        \< 0.001                         \< 0.001
  Midwest                          17.0       14.9                   17.3       16.0      
  Northeast                        16.0       15.2                   18.4       15.4      
  South                            18.8       20.5                   17.1       19.8      
  West                             48.2       49.3                   47.2       48.8      
  **Tumor grade**                                        \< 0.001                         \< 0.001
  G1/G2                            72.6       82.9                   74.9       76.9      
  G3/G4                            27.4       17.1                   25.1       23.1      
  **T stage**                                            \< 0.001                         \< 0.001
  T1                               1.3        2.7                    0.8        2.0       
  T2                               3.6        4.5                    2.9        4.1       
  T3                               75.6       74.0                   71.1       75.5      
  T4                               19.4       18.9                   25.2       18.4      
  **N stage**                                            \< 0.001                         \< 0.001
  N0                               45.9       41.9                   46.7       44.0      
  N1                               30.8       35.7                   28.7       33.2      
  N2                               23.3       22.4                   24.6       22.7      
  **AJCC stage**                                         \< 0.001                         \< 0.001
  II                               43.3       37.3                   43.8       40.7      
  III                              38.8       41.6                   37.5       40.2      
  IV                               17.9       20.7                   18.8       19.0      
  **Total evaluated node count**              \< 0.001                          0.002     
  \< 12                            20.0       30.5                   22.9       24.3      
  ≥ 12                             80.0       69.5                   77.1       75.7      

RSCC, right-sided colon cancer; LSCC, left-sided colon cancer; MAC, mucinous adenocarcinoma; NMAC, non-mucinous adenocarcinoma; SEER, Surveillance, Epidemiology, and End Results; AJCC, American Joint Committee on Cancer

###### 

Kaplan-Meier estimates of overall survival (OS) and hazard ratios weighted by inverse propensity score

  Variable                   *N*     3-y OS (%)   Median OS (months)   Hazard ratio (95% CI)   *P* value
  -------------------------- ------- ------------ -------------------- ----------------------- -----------
  ***Stage IV subgroup***    15448                                                             
  **Tumor side**                                                                               
  Non-mucinous LSCC          6086    32.1         24.5                 1                       
  Non-mucinous RSCC          7624    23.3         16.5                 1.26 (1.21-1.31)        \< 0.001
  Mucinous LSCC              520     22.8         16.5                 1                       
  Mucinous RSCC              1218    20.8         16.5                 1.03 (0.92-1.16)        0.570
  **Mucinous histology**                                                                       
  Non-mucinous LSCC          6086    32.1         24.5                 1                       
  Mucinous LSCC              520     22.8         16.5                 1.27 (1.14-1.41)        \< 0.001
  Non-mucinous RSCC          7624    23.3         16.5                 1                       
  Mucinous RSCC              1218    20.8         16.5                 1.05 (0.97-1.12)        0.207
  ***Stage III subgroup***   32480                                                             
  **Tumor side**                                                                               0.012
  Non-mucinous LSCC          12462   73.9         99.5                 1                       
  Non-mucinous RSCC          16545   69.0         87.5                 1.14 (1.10-1.19)        \< 0.001
  Mucinous LSCC              831     65.6         79.5                 1                       
  Mucinous RSCC              2642    68.2         83.0                 0.96 (0.85-1.09)        0.531
  **Mucinous histology**                                                                       
  Non-mucinous LSCC          12462   73.9         99.5                 1                       
  Mucinous LSCC              831     65.6         79.5                 1.23 (1.11-1.38)        \< 0.001
  Non-mucinous RSCC          2642    69.0         87.5                 1                       
  Mucinous RSCC              16545   68.2         83.0                 1.04 (0.97-1.11)        0.300
  ***Stage II subgroup***                                                                      
  **Tumor side**                                                                               
  Non-mucinous LSCC          11134   80.6         Not reached          1                       
  Non-mucinous RSCC          18226   81.0         Not reached          0.96 (0.91-1.00)        0.072
  Mucinous LSCC              911     80.5         Not reached          1                       
  Mucinous RSCC              3143    81.6         Not reached          0.90 (0.78-1.05)        0.176
  **Mucinous histology**                                                                       
  Non-mucinous LSCC          11134   80.6         Not reached          1                       
  Mucinous LSCC              911     80.5         Not reached          1.04 (0.91-1.19)        0.540
  Non-mucinous RSCC          18226   81.0         Not reached          1                       
  Mucinous RSCC              3143    81.6         Not reached          0.98 (0.91-1.06)        0.692

RSCC, right-sided colon cancer; LSCC, left-sided colon cancer.
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